SEOUL, Sept. 29 (Korea Bizwire) — South Korea’s biosimilar industry is ramping up competition at home and abroad, with companies racing to secure early approvals, expand sales networks, and leverage artificial intelligence as differentiators in a crowded market. At least six biosimilars won approvals or launches globally this month alone, underscoring the pace of expansion. Celltrion [...]
SEOUL, April 22, (Korea Bizwire) — Intensifying competition from biosimilars and the looming expiration of lucrative drug patents have emerged as the foremost concerns for global pharmaceutical, biotech, and medical device companies, according to a 2025 report by Deloitte Korea. The report, titled “Five Key Challenges for the Global Pharmaceutical and Biotech Industry in 2025,” [...]
SEOUL, April 14 (Korea Bizwire) — Celltrion Inc., a major South Korean biopharmaceutical firm, said Monday it has obtained an interchangeability approval for its biosimilar drug for autoimmune disease treatment in the United States. The U.S. Food and Drug Administration (FDA) designated Celltrion’s biosimilar Yuflyma as interchangeable medicine for its original drug Humira in the [...]
SEOUL, March 18 (Korea Bizwire) — Celltrion Inc., a major South Korean biopharmaceutical firm, said Tuesday it aims to achieve 5 trillion won (US$3.46 billion) in sales this year, helped by an expanded biosimilar lineup. The annual target is 40.5 percent higher than the record high of 3.56 trillion won it posted last year. The [...]
Prolia® (denosumab) is indicated to treat certain conditions that lead to high risk for fracture, including osteoporosis in postmenopausal women TVB-009P, Teva’s proposed biosimilar to Prolia, showed Phase 3 clinical results in osteoporosis and is part of Teva’s robust biosimilar portfolio – 7 approved biosimilars and 16 in the pipeline – across critical therapeutic areas such [...]
SEOUL, Aug. 25 (Korea Bizwire) — South Korea’s major pharmaceutical firm Celltrion Inc. said Friday it has completed a license deal with Johnson & Johnson to sell its autoimmune disease treatment biosimilar in the United States. The deal will allow Celltrion’s CT-P43, the company’s ustekinumab biosimilar referencing Stelara, developed by J&J’s pharmaceutical unit of Janssen [...]
SEOUL, Sept. 27 (Korea Bizwire) — South Korean biopharmaceutical firm Celltrion Inc. said Tuesday it has received approval to sell its anticancer biosimilar Vegzelma in Japan. According to the company, Japan’s Ministry of Health, Labor and Welfare recently approved the sale of the biosimilar, also known as CT-P16, which referenced Switzerland-based Roche Holding’s blockbuster pill [...]
SEOUL, July 20 (Korea Bizwire) — South Korean biopharmaceutical firm Samsung Bioepis Co. was in the process of acquiring regulatory approval from European and South Korean drug authorities for SB12, a paroxysmal nocturnal hemoglobinuria (PNH) treatment biosimilar candidate, industry sources said Wednesday. The company has submitted approval applications for SB12, a more affordable version of [...]
SEOUL, April 27 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Wednesday it will begin sales of its autoimmune disease biosimilar Yuflymain in the United States in July 2023. The plan comes as Celltrion has settled a patent dispute with U.S. drugmaker AbbVie Inc. Yuflyma — a biosimilar referencing blockbuster drug Humira — [...]
SEOUL, March 2 (Korea Bizwire) — South Korean pharmaceutical giant Celltrion Inc. said Wednesday that its autoimmune disease biosimilar Yuflyma has begun sales in the domestic market. Yuflyma — a biosimilar referencing blockbuster drug Humira by AbbVie Inc. — is used to treat patients with multiple chronic inflammatory diseases, such as rheumatoid arthritis and psoriasis. [...]